ClinicalTrials.gg
DrugBiological

Eptinezumab clinical trials

Also written Vyepti and ALD403.

studies test it
27
open now
7
in phase 3
16
first study started
2012

How each study uses eptinezumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the eptinezumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
21 Feb 2020 · VYEPTI · BLA 761119 (FDA, Drugs@FDA)
European Union
24 Jan 2022 · Vyepti · EMEA/H/C/005287 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Eptinezumab
21
Eptinezumab-jjmr
4
Lu AG09221
2
ALD403 (Eptinezumab)
2

Brand

Vyepti
8

Development codes

ALD403
4

Studies by the year they started

27 studies that test it; most in 2021 (7)

Studies that test eptinezumab, by start year
YearStudies
20121
20131
20141
20151
20162
20191
20204
20217
20222
20231
20241
20252
20263

By phase

A phase 1/2 study counts in both.

Phase 1
5
Phase 2
2
Phase 3
16
Phase 4
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 23 · Other 4

H. Lundbeck A/S (16) · Alder Biopharmaceuticals, Inc. (6) · Dr George Medvedev (1) · Stanford University (1) · Rigmor Højland Jensen (1) · Sunnybrook Health Sciences Centre (1) · Mayo Clinic (1)

Often tested with

Tested in the same studies.

Galcanezumab (2) · Erenumab (2) · Atogepant (1) · Onabotulinum toxin A (1) · Botulinum toxin type A (1) · Fremanezumab (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3, 3 in phase 3

Studies that test eptinezumab, phase 3 first.

Studies

Open first, then newest update. How each study uses eptinezumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 27

See all 27 studies that test eptinezumab →

Given beside what is tested · 1 — eptinezumab is usual care or a partner of the new treatment

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call eptinezumab · ClinicalTrials.gg INT000985

  • MeSH (NLM) C000628361eptinezumabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 8202AY8I7HEPTINEZUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 2282660One source FDA
  • Wikidata Q28208949eptinezumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C171835EptinezumabOne source FDA
  • DrugBank DB14040One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.